BioCardia Inc. (BCDA)
BCDA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.9903
-2.91% on the day
Market cap
$15.0M
Nano cap
Revenue · 2025
$0
No prior year to compare
Net income · 2025
-$8.2M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/0001437749-26-009587-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BCDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000925741 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$8.2M |
| Operating income | -$8.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $2.5M |
| Total assets | $3.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2025-10-24 |
| Latest annual report FORM 10-K | 10-K | 2026-03-24 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-12 |
| Latest current report FORM 8-K | 8-K | 2026-10-07 |
| Latest proxy FORM DEF 14A | DEF 14A | 2025-11-03 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TCRX | TScan Therapeutics Inc. | $0.2167 | -8.91% | $13.8M |
| ESLA | Estrella Immunopharma Inc. | $0.3140 | -4.44% | $13.7M |
| JSPR | Jasper Therapeutics Inc. | $0.4956 | -10.70% | $16.5M |
| DYAI | Dyadic International Inc. | $0.4253 | +1.00% | $17.0M |
| PLUR | Pluri Inc. | $0.9400 | -3.08% | $11.9M |
| PASG | Passage Bio Inc. | $3.64 | -20.00% | $11.7M |
| INAB | IN8bio Inc. | $1.18 | -4.07% | $11.6M |
| INTS | Intensity Therapeutics Inc. | $3.55 | +7.25% | $11.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier